Literature DB >> 9869174

von Willebrand factor (vWf) as a plasma marker of endothelial activation in diabetes: improved reliability with parallel determination of the vWf propeptide (vWf:AgII).

U M Vischer1, J J Emeis, H J Bilo, C D Stehouwer, C Thomsen, O Rasmussen, K Hermansen, C B Wollheim, J Ingerslev.   

Abstract

Elevated plasma von Willebrand factor (vWf) levels are found in diabetes and other vasculopathies, and predict cardiovascular mortality. vWf is stored and released from endothelial cell secretory granules, along with equimolar amounts of its propeptide (vWf:AgII). In the present study, we examined plasma propeptide levels as a marker of endothelial secretion in vivo, using an ELISA based on monoclonal antibodies. vWf but not propeptide levels are influenced by blood groups, explaining in part the smaller variation in plasma propeptide levels among normal individuals. In both controls and insulin-dependent diabetic patients, we found a close correlation between propeptide and immunoreactive vWf levels (r2=0.54, p <0.0001). vWf and propeptide were elevated in patient subgroups with microalbuminuria or overt diabetic nephropathy, whereas only the propeptide was significantly elevated in the normoalbuminuric subgroup. This observation suggests that in conjunction with vWf, propeptide measurements may improve the identification of endothelial activation, which occurs frequently even without increased urinary albumin excretion. In 12 NIDDM patients, a 3-week diet enriched in monounsaturated fat (MUFA) resulted in parallel decreases in vWf (-22%, p <0.05) and propeptide (-17%, p <0.05) levels, indicating that the experimental diet affected endothelial secretion rather than vWf catabolism. A carbohydrate-enriched control diet did not significantly influence either marker. Our results suggest that concomitant determinations of plasma vWf and propeptide are useful tools to assess endothelial activation in vivo, and reinforce our previous conclusion that a diet rich in MUFA can improve endothelial function in NIDDM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9869174

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  15 in total

1.  Microalbuminuria is associated with impaired arterial and venous endothelium-dependent vasodilation in patients with Type 2 diabetes.

Authors:  A M V Silva; B D Schaan; L U Signori; R D M Plentz; H Moreno; M C Bertoluci; M C Irigoyen
Journal:  J Endocrinol Invest       Date:  2010-03-30       Impact factor: 4.256

Review 2.  Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research.

Authors:  Benjamin M Leon; Thomas M Maddox
Journal:  World J Diabetes       Date:  2015-10-10

Review 3.  Endothelial and platelet markers in diabetes mellitus type 2.

Authors:  Peter Kubisz; Lucia Stančiaková; Ján Staško; Peter Galajda; Marián Mokáň
Journal:  World J Diabetes       Date:  2015-04-15

4.  von Willebrand factor propeptide: biology and clinical utility.

Authors:  Sandra L Haberichter
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

5.  Effects of insulin dependence on inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetes mellitus and coronary atherosclerosis.

Authors:  Charalambos Antoniades; Dimitris Tousoulis; Kyriakoula Marinou; Nikos Papageorgiou; Erini Bosinakou; Costas Tsioufis; Elli Stefanadi; George Latsios; Costas Tentolouris; Gerasimos Siasos; Christodoulos Stefanadis
Journal:  Clin Cardiol       Date:  2007-06       Impact factor: 2.882

6.  The synergistic relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD or death in patients with diabetes: results from the Kidney Early Evaluation Program (KEEP).

Authors:  Amit P Amin; Adam T Whaley-Connell; Suying Li; Shu-Cheng Chen; Peter A McCullough; Mikhail N Kosiborod
Journal:  Am J Kidney Dis       Date:  2013-04       Impact factor: 8.860

7.  Increased active von Willebrand factor during disease development in the aging diabetic patient population.

Authors:  Shuang Feng Chen; Zuo Li Xia; Ji Ju Han; Yi Ting Wang; Ji Yue Wang; Shao Dong Pan; Ya Ping Wu; Bin Zhang; Guang Yao Li; Jing Wei Du; Hen Qiang Gao; Philip G de Groot; Bas de Laat; Martine J Hollestelle
Journal:  Age (Dordr)       Date:  2011-11-27

8.  Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma).

Authors:  A Scheja; A Akesson; P Geborek; M Wildt; C B Wollheim; F A Wollheim; U M Vischer
Journal:  Arthritis Res       Date:  2001-02-19

9.  von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli.

Authors:  Stephen J X Murphy; Soon Tjin Lim; Fionnuala Hickey; Justin A Kinsella; Deirdre R Smith; Sean Tierney; Bridget Egan; T Martin Feeley; Sinéad M Murphy; D Rónán Collins; Tara Coughlan; Desmond O'Neill; Joseph A Harbison; Prakash Madhavan; Sean M O'Neill; Mary-Paula Colgan; James S O'Donnell; Jamie M O'Sullivan; George Hamilton; Dominick J H McCabe
Journal:  Thromb Haemost       Date:  2020-09-15       Impact factor: 5.249

10.  Preseason preparation training and endothelial function in elite professional soccer players.

Authors:  Nikolaos E Androulakis; Nikolaos E Koundourakis; Eleni Nioti; Paraskevi Spatharaki; Despina Hatzisymeon; Ioannis Miminas; Michael G Alexandrakis
Journal:  Vasc Health Risk Manag       Date:  2015-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.